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ABSTRACT 
DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT:  
AN EXPLANATION TO THYROID STUNNING 
MADELEINE M. NORDÉN 
Institute of Biomedicine, Department of Medical Chemistry and Cell Biology,  
The Sahlgrenska Academy at the University of Gothenburg, Sweden 
 
131I is widely used clinically in the treatment of Graves´ disease and differentiated thyroid 
cancer. However, cellular and molecular effects of 
131I irradiation in relation to absorbed dose 
are poorly documented. For instance, it is unknown what absorbed doses give rise to acute or 
delayed  lethality,  DNA  damage  that  is  fully  restorable  by  DNA  repair,  or  may  cause 
permanent genomic instability. The phenomenon of thyroid stunning (i.e. inhibition of the 
iodide uptake in the thyroid gland after a diagnostic test dose of 
131I) indicates that further 
studies are needed to characterize the effects of radiation on the thyroid at the cellular and 
molecular levels. Elucidating the mechanism causing thyroid stunning was the aim of this 
thesis.  
In papers I-II the effects of low absorbed doses of 
131I on TSH-stimulated iodide transport and 
NIS  expression  were  investigated.  Primary  porcine  thyroid  cells  cultured  on  filter  in 
bicameral chambers were continuously exposed to 
131I for 48 h prior to analysis. A significant 
reduction of iodide transport was  seen at  absorbed doses  ≥0.15  Gy, correlating to  down-
regulation of NIS mRNA expression. Notably, stimulation with IGF-I counteracted the effects 
of 
131I irradiation. DNA synthesis and total cell numbers were unchanged at doses ≤1 and 3 
Gy, respectively, indicating that thyroid stunning is independent of radiation effects on cell 
cycle regulation.  
In papers III-IV, a possible correlation between thyroid stunning and radiation induced DNA 
damage mediated by the ataxia telangiectasia mutated (ATM) kinase was investigated. The 
genotoxic agent calicheamicin  1 was used to induce high amounts of DNA double strand 
breaks. Both iodide transport and NIS mRNA expression were significantly reduced by sub-
lethal concentrations of calicheamicin  1. This correlated with global formation of  -H2AX 
and Chk2 nuclear foci activated by ATM. Blockage of DNA-PK enhanced genotoxic induced 
repression  of  NIS  transcription  and  iodide  transport,  supporting  the  hypothesis  that 
131I-
induced thyroid stunning is a stress response to DNA damage. In addition, inhibition of ATM 
diminished  the  effect  of  calicheamicin  1  on  both  iodide  transport  and  NIS  expression 
implying that ATM most likely is a mediator of DNA damage-induced thyroid stunning.  
In conclusion, this thesis provides novel data indicating that thyroid stunning is due to down-
regulation of NIS partially elicited by the ATM-dependent DNA damage response.  
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INTRODUCTION 
Although 
131I is widely used clinically in the treatment of thyroid diseases little is known 
about the cellular and molecular effects of 
131I irradiation in relation to absorbed dose. The 
phenomenon of thyroid stunning, implicating inhibition of the iodide uptake in the thyroid 
gland  after  a  diagnostic  test  dose  of 
131I  indicates  that  further  studies  are  needed  to 
characterize these effects. With the aim to elucidate the mechanism causing thyroid stunning, 
this thesis presents cellular and molecular effects of 
131I irradiation on the thyroid.  
 
The Thyroid Gland 
The thyroid gland consists of two lateral lobes situated on either side of the trachea in the 
anterior part of the neck. The lobes, each being approximately 5 cm long and 3-4 cm wide in 
humans, are connected across the midline by the isthmus, reminiscent of the embryonic origin 
from a common median thyroid anlage. The functional units of the gland are the follicles, 
which are thousands of spherical structures each encircled by a single layer of epithelial cells 
resting on a basement membrane. Each follicle contains an inner follicular cavity called the 
lumen, which is filled with colloid, a proteinaceous fluid enriched of the thyroid prohormone 
thyroglobulin  (TG)  (Nilsson,  2001).  The  follicular  cells  produce  the  thyroid  hormones, 
tetraiodothyronine (T4) and triiodothyronine (T3). Embedded within and between the follicles 
are also the calcitonin-producing C-cells, the second endocrine cell type of the thyroid. 
The surface of the follicular cells is divided into apical and basolateral domains that possess 
distinct structural and biochemical features, as illustrated in figure 1. The basolateral plasma 
membrane  facing  the  extrafollicular  space  exhibits  all  receptors  to  external  signaling 
molecules as hormones, cytokines and growth factors. In the apical or luminal membrane the 
effector molecules of thyroid hormone synthesis, such as thyroperoxidase (TPO) and NADPH 
oxidase,  reside.  The  polarized  phenotype  of  the  cells  provides  the  fundamental  basis  of 
exteriorization of hormonogenesis to the extracellular (luminal) space. This is important not 
only to assemble the hormone constituents and enzymes involved in hormonogenesis but also 
to protect the interior of the cells from noxious hydrogen peroxide and other reactive oxygen 
species generated in large quantities at the apical surface with the purpose to oxidize iodide.   DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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Tight junctions encircling the apical pole of the cells support the polarized distribution of 
membrane proteins by restricting lateral diffusion between the apical and basolateral plasma 
membranes (Nilsson, 2001). The tight junctions also maintain solute gradients established by 
active transport between the luminal and extrafollicular spaces. One such gradient is iodide, 
of central importance to the issues of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Top: Illustration of the anatomical localization of the thyroid gland and the microscopic 
follicle  structure.  Bottom:  An  overview  of  the  polarized  distribution  of  molecules  involved  in the 
different  steps  of  thyroid  hormone  synthesis  in  the  thyroid  epithelial  cell.  See  text  for  further 
comments. M M. NORDÉN 
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Thyroid Hormone Synthesis  
The thyroid hormones regulate developmental growth and metabolism in vertebrates. Ingested 
iodine has an essential role in thyroid physiology as it is incorporated in T3 and T4, without 
this component no thyroid hormones can be formed. Iodine, is  absorbed as iodide in the 
intestine and concentrated 40-fold or more in the thyroid by active transport formerly known 
as  the “iodide pump”  (Wolff, 1964). Now we  know  that iodide uptake is  mediated by a 
symport  mechanism,  further  described  below.  The  negatively  charged  iodide  entering  the 
follicular lumen is unable to bind to the tyrosine residues of TG and is therefore oxidized to 
iodine (I2) by the action of TPO before organification, the enzymatic iodide-protein binding, 
can occur (Eskandari et al., 1997; Smyth and Dwyer, 2002). In addition, this process involves 
TPO-mediated  coupling  of  iodinated  tyrosyls  to  form  the  thyronines  still  within  the  TG 
peptide chain. T3 and T4 are therefore stored in the follicular lumen, covalently bound to TG. 
The  secretion  of  thyroid  hormones  is  initiated  by  endocytosis  of  iodinated  TG  from  the 
follicle lumen, followed by proteolytic cleavage of the prohormone by  lysosmal enzymes 
releasing T3 and T4 into the circulation. 
 
Iodide Transport 
Accumulation of iodide within the gland is required for the efficient formation of thyroid 
hormone  in  the  thyroid.  This  involves  a  two-step  transport  process  in  which  iodide  is 
efficiently extracted from the blood and delivered to  the follicular lumen by  sequentially 
basolateral uptake and apical efflux mechanisms. The most important aspects of thyroidal 
iodide  transport  will  be  summarized  in  the  following  sections  (for  more  comprehensive 
reviews,  see  (Carrasco,  1993;  Levy  et  al.,  1998;  Nilsson,  1999;  Nilsson,  2001;  Riesco-
Eizaguirre and Santisteban, 2006)). 
 
The Sodium Iodide Symporter (NIS) 
Iodide uptake is mediated by the sodium iodide symporter (NIS) that co-transports one iodide 
and two sodium ions into the cell (Eskandari et al., 1997). As shown in figure 2, NIS is an 
integral protein with 13 transmembrane segments, the NH2 terminus facing extracellularly and DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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the COOH terminus facing the interior of the cell (Dohan et al., 2003). The driving force of 
NIS-mediated iodide uptake is the inwardly directed Na
+ gradient generated by the sodium 
potassium adenosine triphosphatase (Na
+/K
+-ATPase). Hence, iodide transport is classically 
inhibited by the Na
+/K
+-ATPase blocking drug ouabain. In addition NIS activity is blocked by 
the competitive inhibitors thiocyanate and perchlorate. However, the mechanism by which 
perchlorate blocks NIS activity has been debated, and recently Dohán et al. (Dohan et al., 
2007) reported that NIS mediates electroneutral transport of perchlorate suggesting that NIS 
translocates different substrates with different stoichiometries.  
 
 
 
Figure 2. Schematic representation of the 13 transmembrane segments of NIS. The amino terminus is 
located at the extracellular end whereas the carboxyl terminus faces the cytosol.  Modified from (De 
La Vieja et al., 2000) 
 
The NIS gene was first cloned and characterized in rat (rNIS) by Carrasco and co-workers 
(Dai et al., 1996). Subsequently NIS in human (hNIS) (Smanik et al., 1996), mouse (mNIS) 
(Perron  et  al.,  2001;  Pinke  et  al.,  2001)  and  pig  (pNIS)  (Selmi-Ruby  et  al.,  2003)  were 
identified. The human NIS gene is mapped to chromosome 19 (19p12-13.2) and encodes a 
glycoprotein of 643 amino acids with a molecular mass of approximately 70-90 kDa (Smanik 
et al., 1996). In humans, mice and rats a single NIS transcript varying in size between 2.9 to 
3.7 kb is detected. However, pNIS consists of two transcripts of 3 kb and 3.5 kb, respectively 
(Selmi-Ruby  et  al.,  2003).  The  most  abundant  pNIS  transcript  is  the  full-length  3.5-kb M M. NORDÉN 
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transcript encoding a protein composed of 643 amino acids similar to the hNIS protein. The 
reason for alternative splicing of pNIS is presently unknown. The pNIS protein presents 85% 
identity  with  the  hNIS  protein  (figure  3)  and  about  79%  with  rNIS  and  mNIS  proteins. 
Cultured porcine thyroid cells were used as an experimental model in all studies presented in 
this thesis. When pNIS expression was investigated by quantitative real time RT-PCR primers 
detecting both pNIS transcripts were used. 
 
 
Figure 3. Alignment of the human and porcine NIS amino acid sequences using BLAST at NCBI’s 
webpage. The sequence of porcine NIS exhibits 85 % identity to that of the human NIS protein. + 
indicates similar amino acids, while – represents a gap.  DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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The cloning of the NIS gene opened up a new field of research that has lead to important 
discoveries regarding the role of NIS-mediated iodide transport in thyroid physiology and 
disease (Riesco-Eizaguirre and Santisteban, 2006). For instance, mutations of hNIS identified 
a novel cause of congenital hypothyroidism (De La Vieja et al., 2000; Dohan et al., 2003; 
Reed-Tsur et al., 2008). The expression of functional NIS is fundamental to the successful use 
of  iodine  isotopes  and other  halides  in  diagnostic  thyroid  scintigraphy  of  various  thyroid 
diseases and for radiotherapy of Graves’ disease and thyroid cancer. It is also known that NIS 
is  expressed  in  many  extra-thyroidal  organs,  e.g.  salivary  gland,  breast,  gastric  mucosa, 
placenta  and  kidney  (Bidart  et  al.,  2000b;  Lacroix  et  al.,  2001;  Spitzweg  et  al.,  2001; 
Spitzweg et al., 1998), although due to the lack of enzymes catalyzing iodination in these 
tissues the retention of radioiodine is much less than in the thyroid. Nevertheless, employing 
NIS-mediated iodide uptake in radiotherapy of non-thyroidal cancer is currently an issue of 
great interest (Spitzweg and Morris, 2002). In this respect, NIS is also suggested to be a novel 
therapeutic  gene  in  genetic  transfer,  targeting  radioiodine  to  tumors  not  expressing 
endogenous NIS (Riesco-Eizaguirre and Santisteban, 2006; Spitzweg and Morris, 2004). 
 
Regulation of NIS Expression and Function 
TSH and Signal Transduction Pathways 
It has been known for many years that TSH stimulates iodide transport into the thyroid gland 
via an adenylate cyclase-cAMP-protein kinase A (PKA) mediated pathway (Carrasco, 1993; 
Dumont  et  al.,  1989).  Accumulating  evidence  indicate  that  this  is  accomplished  by  both 
transcriptional and post-transcriptional regulation of NIS. As indicated in figure 4, TSH via 
cAMP stimulates the NIS promoter involving the NIS upstream enhancer (NUE), which is a 
unique promoter element found only in NIS among the thyroid-specific genes (Taki et al., 
2002). Ohno et al. (Ohno et al., 1999) reported that cAMP regulation of NUE in rat requires 
binding of the thyroid transcription factor Pax8 at two sites to be fully functional, and Taki et 
al.  (Taki  et  al.,  2002)  reported  that  human  NUE  contains  a  Pax8  element  and  a  cAMP 
responsive element (CRE)-like sequence, both necessary for full activity. This indicates that 
absence of either Pax-8 or CRE-like binding proteins (CREB) might explain the reduced hNIS 
gene expression in thyroid carcinomas.  M M. NORDÉN 
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The importance of cAMP in NIS gene regulation is illustrated by observations in chronically 
TSH-stimulated  FRTL-5  cells  in  which  the  catalytic  subunit  of  PKA  is  down-regulated. 
Under  these  conditions,  acute  stimulation  with  a  cAMP  agonist  results  in  increased  NIS 
transcriptional  activity  without  PKA  activation  (Armstrong  et  al.,  1995).  However,  other 
pathways  of  TSH  receptor  (TSHR)  signaling  are  also  implicated  in  the  transcriptional 
regulation of NIS (figure 4). Taki et al. (Taki et al., 2002) showed that both PKA-dependent 
pathways  and  PKA-independent  pathways  are  involved  in  the  stimulation  of  NUE  by 
observing  an  activation  of  NUE  in  response  to  forskolin  treatment  after  chronic  TSH 
stimulation without endogenous PKA, while over-expression of exogenous PKA increases the 
NUE  activity  without  cAMP.  Mitogen-activated  protein  kinase  (MAPK)  signaling  is  also 
regulating NIS expression. For instance, inhibition of MEK/Erk activated Rap1, a member of 
the Ras superfamily of small guanosine triphosphate (GTP)-binding proteins, (Tsygankova et 
al.,  2001),  partially  inhibits  cAMP-induced  NIS  gene  transcription  (Taki  et  al.,  2002). 
However,  the  extent  of  MAPK  activation  in  response  to  TSH/cAMP  varies  between  the 
experimental system (different species and cell lines) and contradictory results have been 
reported (Medina and Santisteban, 2000; Vandeput et al., 2003).  
Activation of p38, another MAPK signaling pathway involving the small GTPase Rac1, may 
also participate in PKA-dependent regulation of NIS. It has been shown that application of the 
p38-MAPK  inhibitor,  SB203580,  significantly  decreased  the  cAMP-induced  NIS  mRNA 
expression in FRTL-5 cells (Pomerance et al., 2000). The same authors reported activation of 
p38-MAPK by reactive oxygen species (Pomerance et al., 2000) which is of interest to this 
thesis since 
131I generates free radicals. Moreover, Pax-8 can also be regulated by redox state 
(Puppin et al., 2004). TSH stimulates the reduction of Pax-8, increases the expression of 
redox factor-1 (Ref-1, also known as apurinic apyrimidinic endonuclease, APE) as well as the 
translocation of Ref-1 into the nucleus (Tell et al., 2000), events resulting in an up-regulation 
of NIS. Furthermore, Ref-1 acts as an apurinic/apyrimidinic endonuclease during the repair of 
cellular alkylation and oxidative DNA damages (Tell et al., 2005).  
 DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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Figure  4.    Simplified  schematic  illustration  of  the  signal  transduction  pathways  involved  in  NIS 
regulation known to date. The figure shows the main TSH/cAMP stimulatory pathways both PKA-
dependent and PKA-independent, and the IGF-I/PI3K pathway that either stimulates or inhibits NIS 
expression depending on species or cell type. See text for further details. BRAF, B-raf oncogene; 
CREB, cAMP responsive element binding protein; MEK, MAPK/Erk kinase; MKK, mitogen activated 
protein kinase kinsae. Modified from (Kogai et al., 2006; Riesco-Eizaguirre and Santisteban, 2006). 
 
Finally, PI3K signaling has been reported to regulate NIS expression. However, the resulting 
effect varies among species and cell types. Garcia and Santisteban (Garcia and Santisteban, 
2002),  showed  that  IGF-1  inhibits  the  cAMP-induced  NIS  expression  through  the  PI3K 
pathway  in  FRTL-5  cells,  and  application  of  the  PI3K  inhibitor  LY294002  significantly 
enhances NIS expression in these cells (Garcia and Santisteban, 2002; Kogai et al., 2008b). 
On the other hand, it has been observed that activation of PI3K increases the NIS expression M M. NORDÉN 
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in the MCF-7 human breast cancer cell line (Knostman et al., 2004). Moreover, Kogai et al. 
(Kogai et al., 2008a) recently reported that the IGF-I/PI3K pathway mediates retinoic acid-
stimulated NIS expression in the same cells. Of particular importance to this thesis porcine 
thyroid cells respond to IGF-I with moderately increased iodide transport and, moreover, IGF-
I  markedly  enhances  TSH-stimulated  iodide  transport  (Ericson  and  Nilsson,  1996).  The 
delayed kinetics of this positive regulation suggests a permissive mode of action. However, it 
is yet unknown if IGF-I stimulates pNIS expression. Thus this was investigated in paper III 
along with evaluation of a putative radioprotective effect of IGF-I in irradiated cells (further 
commented below). 
 
Iodine 
Besides TSH the main regulating factor of NIS-mediated iodide uptake is iodine itself by a 
mechanism called auto-regulation. Already in 1948, Wolff and Chaikoff (Wolff and Chaikoff, 
1948) showed that organification of iodide was blocked in rat thyroids in vivo when iodide 
plasma levels reached a critical high threshold. Since then this phenomenon is known as the 
Wolff-Chaikoff  effect.  A  year  later  the  same  authors  (Wolff  et  al.,  1949)  reported  an 
adaptation mechanism or escape from the effect appearing two days after its onset. Eventually 
this resulted in restored capacity of iodine organification. After all these years the Wolff-
Chaikoff effect still remains poorly understood although it is believed that the inappropriate 
formation of iodolipids is an initiating event (Boeynaems et al., 1995). Of central importance, 
inhibition of TPO activity with methimazole (MMI) abolishes the negative effect of excess 
iodine on iodide uptake (Grollman et al., 1986), indicating that organification is required. 
MMI is used experimentally to avoid the Wolff-Chaikoff effect in iodide transport studies. In 
vivo experiments indicate that the escape from the Wolff-Chaikoff effect is manifested by 
down-regulation of NIS at the transcriptional level (Eng et al., 1999; Spitzweg et al., 1999). 
However, the precise mechanism by which the NIS expression is turned off has not been 
elucidated. It should also be mentioned that high doses of iodide decrease the NIS protein 
levels in a dose-dependent manner without affecting the NIS gene transcription in FRTL-5 
cells  (Eng  et  al.,  2001).  This  suggests  that  iodide  may  modulate  NIS  also  post-
transcriptionally. DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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Other Hormones and Cytokines 
Transforming growth factor-beta (TGF- a potent inhibitor of thyroid cell proliferation has 
been shown to decrease TSH-induced NIS expression as well as NIS function in FRTL-5 cells 
(Pekary and Hershman, 1998). This may be part of general dedifferentiation induced by TGF-
  in  many  epithelial  cell  types  including  thyrocytes  (Grände  et  al.,  2002).  As  already 
mentioned, IGF-I decreases the NIS expression in the same cells (Garcia and Santisteban, 
2002). rNIS transcription is also negatively regulated by estrogen (Furlanetto et al., 2001). 
The authors hypothesized that the effect of sex steroids on NIS-mediated iodide uptake might 
contribute to the increased susceptibility to goiter in women (Furlanetto et al., 2001).  
Studies on cultured thyroid cells collectively indicate that NIS is negatively affected by pro-
inflammatory cytokines. In fact, decreased iodide uptake is observed in response to the most 
important  cytokines,  i.e.  tumor  necrosis  factor  (TNF)- TNF- ,  interferon  (IFN)- , 
interleukin (IL)-1 , IL-1  and IL-6, implicated in autoimmune thyroid disease (Ajjan et al., 
1998; Rasmussen et al., 1994; Spitzweg et al., 1999). Moreover, Caturegli et al. (Caturegli et 
al., 2000) showed significantly reduced NIS mRNA and protein levels in transgenic mice 
developing  hypothyroidism  following  conditional  expression  of  IFN- in  the  thyroid, 
indicating a direct role of NIS repression in the pathophysiology of autoimmune thyroiditis  
As  the  cytokines  affecting  NIS  act  through  distinct  intracellular  signaling  pathways  it  is 
conceivable  to  assume  that  they  trigger  or  deactivate  a  common  down-stream  regulatory 
mechanism, possibly shared by other stress responses in the thyroid cell.  
 
Post-transcriptional Regulation of NIS 
Riedel et al. (Riedel et al., 2001) showed that NIS is also subjected to post-transcriptional 
regulation. It was demonstrated that NIS is a phosphoprotein and that the phosphorylation 
pattern  is  altered  by  TSH  in  a  PKA-dependent  manner.  Furthermore,  TSH  increases  the 
already long half-life of the NIS protein, and stimulates the trafficking of NIS to the plasma 
membrane.  In  subsequent  studies  it  was  shown  that  Glu  543,  putatively  located  on  the 
cytoplasmic side of transmembrane segment XIII of NIS, plays an important role for targeting 
intracellular NIS to the cell surface (De la Vieja et al., 2005).  Faulty trafficking of NIS likely 
explains the recognition of decreased iodide uptake activity in some thyroid cancers although M M. NORDÉN 
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NIS  is  over-expressed  (Arturi  et  al.,  2000;  Dohan  et  al.,  2001;  Saito  et  al.,  1997). 
Investigations of tissue extracts from hypofunctioning benign and malignant thyroid tumors 
have  revealed  that  hNIS  exhibiting  a  predominant  intracellular  localization  is  non-
glycosylated (Trouttet-Masson et al., 2004). 
 
Epigenetic Events 
Epigenetic modifications play an important role in the regulation of gene expression both 
normally and in disease, mainly recognized in cancer. The acetylation status of histones is 
determined by the activities of histone acetyltransferases and histone deacetylase (HDAC) 
(Marks et al., 2001). HDAC inhibitors, e.g. depsipeptide, trichostatin A (TSA) and valproic 
acid (VPA) constitute a new group of anti-cancer drugs that reduce transformed cell growth 
both in vitro and in vivo and induce redifferentiation or apoptosis in tumor cells. Interestingly, 
HDAC inhibitors have been shown to reinduce NIS expression, suggesting means to improve 
the use of radioiodine therapy in poorly differentiated thyroid cancer. 
DNA  methylation  of  CpG  islands  in  critical  gene  promoter  regions  results  in  heritable 
inhibition of gene expression, and abnormal patterns of DNA methylation are consistently 
observed  in benign and malignant human thyroid tumors (Baylin, 1997; Matsuo et al., 1993). 
The demethylating agent, 5-azacytidine, is able to restore NIS expression and radioiodide 
uptake in some thyroid cancer tumors (Neumann et al., 2004; Venkataraman et al., 1999). 
 
Apical Iodide Efflux 
In order to incorporate iodide into TG it must be delivered to the outer facet of the apical cell 
surface. This process is known as apical iodide efflux, executed by less well-characterized ion 
channels or carriers. The iodide permeability of the apical membrane varies depending on 
functional state of the thyroid cells, and TSH stimulates iodide efflux unidirectionally towards 
the apical compartment in cultured polarized thyrocytes (Nilsson et al., 1990). Importantly, 
and in contrast to the effect of TSH on NIS expression and function, apical efflux of iodide is 
a rapid process noticed within minutes after the addition of TSH. The molecular correlate of DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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this  TSH-regulated mechanism is  not  yet  identified, although some candidates  have been 
suggested (figure 1).  
Pendrin  is  a  chloride-iodide  transport  protein  located  at  the  apical  end  of  the  thyroid 
epithelium (Bidart et al., 2000a; Royaux et al., 2000), and functions by exchanging chloride 
with  iodide  (Scott  et  al.,  1999).  Pendrin  requires  high  concentrations  of  iodide  in  the 
cytoplasm in order to transport iodide hence its function depends on NIS (Yoshida et al., 
2004).  Mutations in the gene encoding pendrin lead to Pendred’s syndrome, a phenotype 
consisting mainly of congenital  deafness  and  goiter. The thyroid  of Pendred’s  patients  is 
characterized by impaired transport and retention of iodide and enlarged follicles (Reardon 
and Trembath, 1996). The expression of pendrin is transcriptionally stimulated by TSH, but 
pendrin-mediated iodide efflux seems to be cAMP-independent involving protein kinase C 
(Muscella et al., 2008).  
The  human  apical  iodide  transporter  (hAIT)  sharing  structural  homology  with  NIS  was 
originally proposed to mediate iodide efflux across the apical membrane (Lacroix et al., 2004; 
Rodriguez et al., 2002). However, it has now become clear that hAIT does not transport 
iodide, but instead transclocate monocarboxylic acids such as lactate, pyruvate, propionate, 
butyrate and nicotinate across membranes (Coady et al., 2004; Miyauchi et al., 2004; Paroder 
et al., 2006). This molecule has therefore been renamed to Na
+/monocarboxylate transporter 
(SMCT). 
For simplicity reasons and since the molecular mechanism still remains elusive, apical efflux 
was not directly monitored in the iodide transport experiments conducted in the present thesis. 
Data to be presented do not infer an effect on this parameter, although minor contributions 
cannot be excluded. This will not be further commented on other than stated here.  
This  ends  the  overview  of  iodide  handling  in  the  thyroid.  The  following  parts  of  the 
Introduction will focus on effects of ionizing radiation and cellular responses to DNA damage 
of relevance to the specific issues addressed in this thesis. Some clinical aspects of thyroid 
cancer and the use of radioiodine for diagnosis and therapy will also be highlighted.  M M. NORDÉN 
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Internal Radiation Effects on the Thyroid 
Oncogenesis 
Ionizing radiation is a well-known risk factor for the development of thyroid cancer but the 
initiating genetic aberrations leading to tumorigenesis are poorly understood (Mizuno et al., 
2000). The risk to develop thyroid cancer from internal 
131I irradiation accumulated in the 
thyroid is considered to be much higher in the growing gland illustrated by the high incidence 
of papillary thyroid cancer amongst children in the surrounding area of Chernobyl reported 
since the accident in 1986 (Williams, 2002). Conceivably, cells with a higher mitotic index 
are more susceptible to acquire permanent DNA lesions that can be propagated to progeny 
cells.  Radiation-induced  thyroid  cancer  was  recently  shown  to  exhibit  a  distinct  genetic 
signature (Port et al., 2007), contradicting previous reports (Detours et al., 2005). It is also 
known that the presence of BRAF mutations in thyroid cancers from atomic bomb survivors 
correlates  with  the  absorbed  dose  (Takahashi  et  al.,  2007),  although  this  is  also  debated 
(Powell N, 2005). Presently, there are no reliable experimental models that allow study of 
early genetic aberrations generated by 
131I mimicking internal radiation. Nevertheless, it can 
be assumed that thyroid cells exposed to ionizing radiation will obtain DNA damage by free 
radicals  eventually leading to genomic instability and permanent lesions  (Hall and Holm, 
1998).  
In paper I and III we studied the cells responses to low absorbed doses of 
131I and if DNA 
lesions affect the iodide transport capacity. 
 
Therapy 
The discovery of X-rays in 1895 by Wilhelm Condrad Röntgen and of natural radioactivity a 
few  months  later  by  the  physicist  Henry  Becquerel  were  two  breakthroughs  in  medicine 
(Bernier et al., 2004).  Ever since discoveries in radiation physics, chemistry and biology has 
aimed to develop more accurate, efficient anticancer therapies that are less harmful to normal 
tissues.  Medical  uses  of  radiation  include  diagnosis  of  disease,  therapy  and  research. 
Diagnosis covers a wide range of exams from routine x-rays to complex CT scans and the 
injections of radioactive material for nuclear medicine imaging. In general, radiation therapy 
involves delivering a large dose of radiation to a small area of the body. Therapy is mainly DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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directed to kill tumor cells as part of the treatment of cancer. The only exception to this in 
medicine today is the use of 
131I in the treatment of hyperthyroidism due to Grave’s disease, 
with the aim to ablate the function of a hyperactive gland. 
131I is ingested orally as sodium 
iodine of high specific activity either as a liquid solution or as capsules. The radioiodine is 
absorbed in the upper intestine and circulates in the blood throughout the body. However, 
since iodine is rapidly and efficiently taken up by thyroid cells, there are few side effects of 
131I irradiation in other tissues (although other organs expressing NIS may be affected).  
Malignant tumors arising from the thyroid epithelial cells are classified according to their 
histopathological  features  in  papillary  and  follicular  carcinomas,  which  may  be  highly, 
intermediate  or  poorly  differentiated,  and  anaplastic  thyroid  carcinoma  that  have  lost  all 
characteristics of the thyrocyte (Miccoli et al., 2007). Depending on the tumor type different 
treatment modalities comprising surgery, external radiation, radioiodine (
131I) therapy, and 
chemotherapy are employed (Spitzweg and Morris, 2004). The majority of thyroid cancers 
and its  metastasis display  a diminished iodide uptake compared to  normal  thyroid tissue. 
However, in many cases the iodide uptake is sufficient for radioiodine (
131I) treatment.  Total 
loss of differentiation leads  to  inability of accumulating iodide and poor prognosis  if the 
tumor is not detected early and radically removed by surgery. 
There is a reduced expression of both NIS mRNA and protein in papillary and follicular 
thyroid cancer (Arturi et al., 1998; Caillou et al., 1998; Lazar et al., 1999; Ringel et al., 2001; 
Smanik et al., 1997).  A low or absent NIS expression may be due to silencing of the NIS 
promoter e.g. by hypermethylation (Matsuo et al., 1993). To date several compounds have 
partially succeeded to reinduce endogenous NIS expression in thyroid cancer. Such agents are 
retinoic  acid,  peroxisome  proliferator-activated  receptor-   (PPAR- )  agonist,  HDAC 
inhibitors  and  demethylating  agents  that  are  reviewed  in  (Kogai  et  al.,  2006;  Riesco-
Eizaguirre  and  Santisteban,  2006).  Recent  studies  based  on  immunohistochemistry  and 
reverse-transcriptase (RT)-PCR have revealed that in many thyroid cancer patients with a 
poor radioiodine uptake the tumor cells paradoxically over-express NIS, but the NIS protein is 
retained in the cytoplasm and not targeted to the cell surface (Dohan et al., 2001; Saito et al., 
1998;  Wapnir  et  al.,  2003).  These  observations  indicate  that  loss  of  iodide  uptake  in 
differentiated thyroid cancer may be due to impaired targeting or insufficient retention of NIS 
in the plasma membrane rather than decreased expression of the NIS gene. Restoration of the M M. NORDÉN 
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trafficking of NIS to the tumor cell surface, if possible, would be a nice strategy to increase 
the efficacy of 
131I therapy in a subset of thyroid cancer cases.  
The observation that NIS is also expressed in extra-thyroidal tissues has proposed the use of 
NIS as a novel therapeutic gene in human cancer in order to apply radioiodide therapy to 
nonthyroidal cancers, especially breast cancer. Hydrocortisone, isobutylmethylxanthine and 
dexamethasone have all been reported to  stimulate retinoic  acid-induced NIS protein and 
plasma  membrane  targeting  in  MCF-7  cells  (Dohan  et  al.,  2006;  Kogai  et  al.,  2005; 
Unterholzner et al., 2006). Gene transfer of NIS is one of the most promising and well-studied 
gene strategies in oncology today (Spitzweg and Morris, 2004).  
 
Thyroid Stunning 
After tumor surgery 
131I is used to destroy any possible thyroid or tumor remnants. If the 
131I 
uptake is sufficient this treatment has the potential to be curative. It is also important to ablate 
the  normal  thyroid  tissue,  allowing  future  relapse  of  cancer  to  be  detected  by  routine 
monitoring  of  the  TG  level  in  blood.  The  amounts  of  remnants  to  be  irradiated  have 
traditionally  been  estimated  with  diagnostic  scintigraphy  using  low  amounts  of 
131I 
administered a few days prior to radiotherapy. However, several studies have reported that the 
diagnostic exposure to 
131I may seriously diminish subsequent uptake of the therapeutic dose, 
a phenomenon known as thyroid stunning. Some authors claim that the stunning effect may 
eventually compromise the therapeutic efficiency and long-term outcome of the radioiodine 
treatment (Kalinyak and McDougall, 2004; Medvedec, 2005; Morris et al., 2003; Park et al., 
1997). Whereas, other experts argue against a clinical significance of stunning and infer this 
as an early therapeutic effect of the ablative dose rather than being related to the preceding 
diagnostic procedure (Bajen et al., 2000; Cholewinski et al., 2000; McDougall, 1997). At the 
start of this thesis work thyroid stunning was still a controversial issue, augmented by the lack 
of experimental data of the mechanism. A short overview of the most important reports on the 
clinical observations and recent experimental data is therefore given below. 
Although being recognized more than 50  years ago  (Rawson et al., 1951), the first clear 
clinical indication of thyroid stunning was published in 1986 by Jeevanram et al. (Jeevanram 
et al., 1986). They studied 52 patients who received five different doses of 
131I for diagnostic 
imaging and found 25 % inhibition of the following therapeutic uptake of 
131I in patients who DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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delivered a dose less than 17.5 Gy. Additional 3-fold (75 %) reduction of the ablative 
131I 
uptake could be seen when a higher diagnostic dose estimated to deliver 35 Gy was used.  
In 1994 Park and colleagues (Park et al., 1994) showed an increasing incidence of thyroid 
stunning after administration of larger 
131I diagnostic activities. Specifically, a 40 % reduction 
in iodide uptake was observed after 111 MBq, and the corresponding figures were 67 % and 
88 % after 185 MBq and 370 MBq, respectively. A later study from the same group (Park et 
al., 1997) compared the outcome of 
131I treatment in patients who had diagnostic scans of 
111-370 MBq of 
131I versus 11.1 MBq of 
123I. In this paper it was hypothesized that the lack 
of  beta  emissions  from 
123I  would  eliminate  the  stunning  phenomenon.  Even  though  no 
statistical significant difference between the two groups was observed the data supported the 
concept of thyroid stunning with 
131I. 
In another study the influence of diagnostic scans using either 37 MBq or 111 MBq 
131I, 
followed by a 3.7 GBq ablative dose were compared (Muratet et al., 1998). Interestingly, 
ablation was successful in 76 % of patients receiving 37 MBq but only 50 % in those who 
received 111 MBq for diagnostic imaging. 
Bajen et al. (Bajen et al., 2000) reported a reduced uptake in 21 % of the post-therapy scans 
compared to the diagnostic ones (185 MBq 
131I) that were performed in average 8 weeks later. 
Despite this the authors claimed that no stunning could be observed, instead the decreased 
uptake of iodide was suggested to be due to a therapeutic effect.  
One important factor that may explain conflicting results on the existence of thyroid stunning 
is the time-interval between the diagnostic and therapeutic administration of 
131I, which vary 
considerably in different reports. For instance, McDougall (McDougall, 1997) showed that 
the therapeutic uptake efficacy was only reduced 3.5 % after a 74 MBq 
131I diagnostic scan, 
given within a 24 hour time period. The possibility, that early treatment after the diagnostic 
scan may eliminate stunning is supported by others (Cholewinski et al., 2000). 
The first experimental study addressing the question of thyroid stunning was conducted in our 
laboratory (Postgård et al., 2002). By using differentiated porcine thyrocytes growing on a 
filter in a bicameral chamber system, it was shown that the TSH-stimulated iodide transport 
was  significantly  reduced  three  days  after 
131I  irradiation,  and  that  the  level  of  transport 
inhibition  was clearly dependent  on the received absorbed dose. A 50% reduction of the 
iodide transport could be seen after an absorbed dose of 3 Gy, whereas at 80 Gy the transport M M. NORDÉN 
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was almost untraceable. Importantly, under the experimental conditions irradiation did not 
influence  the  viability  of  the  cells.  Most  likely  due  to  that  the  cells  were  cultured  to 
confluence before experiment, implicating that most cells had exited the cell cycle and were 
quiescent. This ruled out the possibility of cell death as an explanation for thyroid stunning at 
least in vitro. 
In  summary,  today  most  researchers  and  clinicians  agree  that  thyroid  stunning  is  a  real 
phenomenon. However, the mechanisms behind this phenomenon still remain elusive. The 
general aim of this thesis was to identify some of its characteristics at the molecular and 
cellular levels. 
 
DNA Damage 
Human cells are continuously exposed to a wide range of DNA-damaging agents. During 
every cell cycle the human genome is exposed to genotoxic events and it has been estimated 
that approximately 10 000 DNA lesions occur each day in a metabolically active mammalian 
cell.  DNA-damage  can  also  be  induced  exogenously  by  exposure  to  UV-light,  ionizing 
radiation and chemical mutagens. In order to combat these attacks on the genome, the cell has 
evolved a response system that induces cell cycle arrest to allow sufficient time to repair the 
induced damages.  The  cellular  response to  genotoxic stress  also  activates the  appropriate 
DNA repair pathway or, in the case of irreparable damage, induces apoptosis. Different types 
of  DNA  damage  induce  varying  types  of  lesions,  including  strand  breaks.  Depending  on 
whether only one or both DNA strands are broken they are described as single-strand breaks 
(SSBs) or double-strand breaks (DBSs), respectively. DSBs are considered to be the most 
lethal lesion since incorrect repair might lead to mutations or genomic instability (Jackson, 
2001).  
Next some general aspects of the DNA damage response and related details of particular 
relevance to this thesis will be outlined.  DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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Ionizing Radiation 
Ionizing radiation consists of highly-energetic particles or electromagnetic waves that can 
ionize at least one electron from an atom or molecule. These ionizations can damage living 
tissue by generating free radicals, break chemical bonds, produce new chemical bonds  or 
cross-link macromolecules that regulate vital cell processes. Ionizing radiation mostly induces 
SSBs and only 2-5 % of the breaks are DSBs (Elmroth et al., 2003). For over 50 years it has 
been known that exposure of cells to ionizing radiation delays the normal progression through 
the cell cycle (reviewed by (Iliakis et al., 2003)). Early studies further showed that the cell 
cycle arrest reflects a window that provides time necessary for the irradiated cell to cope with 
the induced damage by facilitating DNA repair before mitosis (Lucke-Huhle, 1982; Tobey, 
1975; Walters et al., 1974). This notion was later supported in studies on cells from ataxia 
telangiectasia (A-T) patients, which in culture were prone to die after exposure to ionizing 
radiation due to a shortened delay in their cell cycle progression (Painter and Young, 1980).  
 
Radioiodine Nuclides: 
131I and 
125I  
The  physical  characteristics  of  radioiodine  isotopes  used  in  this  study  will  be  shortly 
described. 
131I is a beta-particle emitter, with the maximal beta-energy of 606 keV and the 
mean energy of 191 keV, with a physical half-life of 8.02 days (Robbins and Schlumberger, 
2005). Except from emitting beta-particles the 
131I atom also emits gamma-rays the major 
being at 364 and 637 keV. These beta- and gamma-radiations account for 90% of the total 
radiation  from 
131I,  where  gamma-radiation  only  contributes  with  10%.  Since  the  beta-
particles are unable to penetrate deep into tissue, large doses of 
131I may be administered 
without damaging surrounding tissues. As mentioned earlier internal irradiation with 
131I is 
frequently used as therapeutics in thyroid diseases (Robbins and Schlumberger, 2005). In 
1946 Seidlin et al. was the first one to report the use of radioiodine to treat thyroid cancer 
(Seidlin S, 1946). Ionizing radiation disrupts chemical bonds throughout the cell, causing 
DNA damage and triggering cellular arrest and ultimately cell death. 
125I is a radioisotope of iodine that emits gamma-rays with the maximal energy of 35 keV. 
Due to its suitable half-life of about 60 days, it is frequently used in in vitro experiments as a 
tracer to evaluate the cells capacity to accumulate or transport iodide, a technique applied in M M. NORDÉN 
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this thesis.  About 70% of the emitted energy comes from photons and 30% by electrons. The 
electron energy from 
125I is deposited locally with a very short range.  
The susceptibility of proliferating thyroid cells to ionizing radiation from 
131I was investigated 
in paper I. The effect of 
131I on NIS-mediated iodide transport was mainly studied in papers I 
and II. 
 
Genotoxic Drugs 
Genotoxic drugs are best exemplified by chemotherapeutic agents used in cancer treatment. 
This is a heterogenous group of chemical compounds that affect nucleic acids and alter their 
functions by different mode of actions. The drugs may directly bind to DNA or they may 
indirectly lead to DNA damage by affecting enzymes involved in DNA replication. Hence, 
proliferating cells are more sensitive to genotoxic agents due to their active synthesis of new 
DNA than quiescent or senescent cells. If the damage is severe enough the cell undergoes 
apoptosis.  The  radiomimetic  action  of  some  of  these  drugs  can  be  employed  also  in 
experimental studies. The features of one such agent used in papers III and IV are described in 
the next paragraph. 
 
Calicheamicin γ 1 
Calicheamicin    (CLM),  figure  5,  is  an  incredibly  potent  cytotoxic  agent  working  by 
destroying the DNA in cells. It is an enediyne antibiotic naturally produced by the bacteria 
Micromonospora echinospora ssp. calichensis, discovered in the mid 80s during a field trip 
aiming to find new fermentation-derived antitumor antibiotics (Lee et al., 1987; Lee et al., 
1991).  CLM  is  an  efficient  inducer  of  DSB,  with  a  DSB:  SSB  ratio  of  ~1:3,  since  the 
compound binds to double-stranded DNA with high affinity. Specifically, CLM contains two 
radical centers that become positioned close to the backbone of DNA in which the drug binds 
to the minor groove, as it reduces a trisulfide in the DNA helix (Elmroth et al., 2003). The 
preference of inducing DNA DSBs is reflected by a strong DNA damage response typical for 
this kind of DNA lesions in cultured cells (Ismail et al., 2005). The potency to induce DNA 
damage makes CLM an attractive chemotherapeutic agent. However, because of pronounced DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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side-effects  of systemically administered CLM  it is so  far only used in antibody-targeted 
chemotherapy (Gemtuzumab Ozogamicin; Mylotarg, Wyeth-Ayerst, St Davids, PA, USA) of 
e.g. relapsed acute myeloid leukemia (Pagano et al.). The antibody conjugated-drug binds to 
CD33 on the leukemic cell surface after which the compound is internalized and released in 
the lysosomes before reaching nuclear DNA.  
 
 
 
Figure  5.    Schematic  picture  of  the  enediyne  antibiotic  Calicheamicin  that  efficiently  induces 
double strand breaks in DNA. Modified from (Nicolaou et al., 1993). 
 
Cell Cycle 
In order to understand the DNA damage response to DSB a short summary of the mechanisms 
controlling  the  cell  cycle  is  warranted.  The  cell  cycle  comprises  a  range  of  sequential 
processes that eventually results in the duplication of a cell (Elledge, 1996). The four main 
stages of the cell cycle are: G1 (presynthesis), S (DNA synthesis), G2 (premitotic) and M 
(mitotic) phases. Quiescent cells are in a post-mitotic physiological state referred to as G0. 
To ensure the fidelity of cell division, cells have evolved regulatory circuits or checkpoints 
that monitor successful completion of distinct cell cycle events. There are two classes of such 
regulatory circuits, intrinsic and extrinsic. The intrinsic mechanisms act in each cell cycle to 
order the sequence of events ultimately leading to mitosis, whereas the extrinsic mechanisms 
are induced only when the cell encounter a defect (Elledge, 1996). The transition from one 
cell cycle stage to  the  next  is dependent  upon  the activation of  cyclin-dependent  kinases 
(CDKs)  that  in  turn  are  both  positively  and  negatively  regulated  by  other  kinases  and M M. NORDÉN 
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phosphatases altering their phosporylation state. Moreover, binding to inhibitors and other 
proteins might also alter their activity (Sherr, 1996).  
As described next, cell cycle checkpoints are activated by signals generated by DNA damage 
leading to delay or arrest of cell cycle progression.  
 
DNA Damage Response Mechanisms 
As depicted in figure 6, the DNA-damage response pathway is a signaling cascade, consisting 
of sensors, transducers and effectors that detects damaged DNA at the same time as it induces 
the transcription of DNA repair genes (Elledge, 1996). Depending upon the phase in which 
the  DNA  damage  is  sensed  the  cells  arrests  in  the  G1  phase  of  the  cell  cycle  (G1-S 
checkpoint), slows down S phase (S phase checkpoint) or arrests cells in the G2 phase (G2-M) 
phase checkpoint). Some of the key signaling and effector molecules implicated in the DNA 
damage response have a central role in this thesis work and are therefore presented in more 
detail.   
 
Figure 6. Schematic picture of the DNA damage pathway consisting of sensors, transducers and 
effectors. See text for details. Modified from (Jackson, 2001). DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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Ataxia-Telangiectasia Mutated (ATM) 
The ATM protein is the product of the gene that is mutated in the rare, autosomal-recessive 
inherited human disorder ataxia-telangiectasia (A-T) characterized by amongst many organ 
dysfunctions, enhanced radiosensitivity and genomic instability (Morio and Kim, 2008). The 
ATM  gene  cloned  in  1995  encodes  a  large  (370  kDa)  protein  that  belongs  to  the 
phosphoinositide  3-kinase  (PI3K)  like  family  (Savitsky  et  al.,  1995).  ATM  possesses 
serine/threonine kinase  activity  regulating  cell-cycle checkpoints  and is involved  in  DNA 
repair and recombination via protein phosphorylation of down-stream substrates, to be further 
discussed below (Abraham, 2004; Kastan and Lim, 2000; Shiloh, 2003). In fact, ATM is at 
the top of the DNA damage signaling cascade responding specifically to DNA DSBs. Cells 
from A-T patients show abnormal responses to ionizing radiation, checkpoint alterations in 
the cell cycle, and increased chromosomal breakage and telomere end fusions (Kastan and 
Lim, 2000). Conversely, the response of  ATM -/-  cells  to  ultraviolet irradiation  and base 
damaging agents are relatively normal, further indicating that ATM is the initial and principal 
transducer in the response to DNA DSB (Shiloh, 2003). Additionally, the broad range of other 
abnormalities found in patients and cultured cells lacking ATM reveals the large number of 
substrates of ATM in various signaling pathways.  
To date, the mammalian members of the PI3K-like family include five protein kinases: ATM, 
ataxia-telangiectasia- and Rad3-related (ATR), human SMG-1(hSMG-1), mammalian target 
of rapamycin (mTOR) and the catalytic subunit of the DNA-dependent protein kinase (DNA-
PKcs) of which all but mTOR are involved in the DNA-damage response (Shiloh, 2006). 
DNA-PK is similar to ATM in that it mainly responds to DSBs. ATR primarily transduces 
signals deriving from UV damage and blockage of replication forks (Nyberg et al., 2002; 
Zhou and Elledge, 2000).  
 
ATM Activation 
Under normal  conditions  ATM is  mainly  located in  the nucleus as  an inactive dimer.  In 
immediate  response  to  double-stranded  lesions  ATM  is  converted  into  kinase-active 
monomers by an autophosphorylation  on at  least  three sites:  serine 367, serine 1893 and 
serine 1981 (Bakkenist and Kastan, 2003; Kozlov et al., 2006; Shiloh, 2003). It is believed M M. NORDÉN 
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that activated ATM exists both bound to the chromatin and freely movable throughout the 
nuclear matrix (Shiloh, 2003). As shown in figure 7, activated ATM phosphorylates a large 
number of key regulatory proteins e.g. p53, MDM2, BRCA1, CHK2, MDC1 and NBS1 that 
mediate  down-stream  signaling  either  by  promoting  or  impairing  the  activity  of  their 
respective target molecules implicated in checkpoint activation.  
As a part of the activation process in response to DNA damage ATM associates with the 
Mre11/Rad50/Nbs1 (MRN) multi-protein complex, which is known to tether and process the 
broken DNA ends as well as augment the DNA-damage signal (Lee and Paull, 2007; Shiloh, 
2006). Mutations in the genes of two members of this complex NBS1 and MRE11 have been 
described in Nijmegen breakage syndrome and A-T-like disorder, respectively (Lavin, 2008), 
indicating the central importance to maintain genomic stability.  
 
Figure  7. Simplified scheme of ATM activation and signaling to downstream substrates in response to 
DNA double-strand breaks. ATM phosphorylates or mediates the phosphorylation of many different 
proteins  to  ensure  the  regulation  of  one  specific  checkpoint.  SMC1,  structural  maintenance  of 
chromosomes protein-1; BRCA1, breast cancer susceptibility protein-1; FANCD2, Fanconi anaemia 
complementation group D2. Modified from (Lavin, 2008). DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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ATM has also been found in the cytoplasm, associated with peroxisomes and endosomes 
(Lim  et  al.,  1998;  Watters  et  al.,  1999)  and  several  of  the  abnormalities  seen  in  ATM-
deficient cells provide evidence for a more general signaling role of ATM besides direct 
involvement in  DNA damage. These abnormalities  include reduced internalization of  cell 
surface-bound  molecules,  defective  Ca
2+  mobilization,  depolarization  in  response  to 
extracellular ions, and defective signaling through the epidermal growth factor (EGF) receptor 
(Lavin, 2008). In addition, ATM seems to participate in the regulation of insulin signaling 
through activation of the PKB/Akt pathway, which may explain the insulin resistance seen in 
some A-T patients (Viniegra et al., 2005). 
 
ATM Key Substrates 
The diversity of ATM-mediated responses to DSBs verifies that it has many substrates, some 
of which will be briefly mentioned below. However, it should be emphasized that more ATM 
targets  are  yet  likely  to  be  discovered.  In  controlling  a  specific  process  ATM  directly 
phosphorylates target proteins or activates other kinases that act as downstream mediators. 
For instance, p53, being the main regulating component of the G1 DNA damage checkpoint, 
regulates the transcription of the gene encoding the CDK2-cyclin-E inhibitor p21, also known 
as WAF1 or CIP1 (Kastan and Lim, 2000). Activated ATM phosphorylates p53 at serine 15 
as well as two proteins involved in controlling p53 function and expression levels; MDM2 
and Chk2. The oncogenic protein MDM2 is an important regulator of p53 degradation and 
has been shown to be phosphorylated on serine 395 by ATM in response to ionizing radiation 
resulting  in  accumulation  of  p53  in  the  nucleus  (Khosravi  et  al.,  1999).  Chk2  is  a 
serine/threonine kinase that is phosporylated by ATM in response to ionizing radiation. Chk2 
is structurally unrelated to Chk1, which is phosphorylated by ATR, but the two checkpoint 
kinases exhibit overlapping substrate specificity (Bartek et al., 2001; Matsuoka et al., 1998). 
In  mammals  Chk2  is  phosphorylated  on  threonine  68  (Thr68)  by  ATM  which  probably 
induces a conformational change of the protein. Chk2 in turn phosphorylates p53 on serine 
20.  In  addition,  activated  Chk2  induces  G1/S  cell  cycle  arrest  and/or  S-phase  delay  by 
phosphorylating Cdc25A and contributes to the G2/M block by phosphorylating the mitosis-
promoting phosphatase Cdc25C (Bartek et al., 2001) M M. NORDÉN 
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In  paper  III  we  analyzed  Chk2  phosphorylation  and  foci  formation  to  determine  ATM-
dependent  cell  cycle  arrest  following 
131I  irradiation  and  exposure  to  CLM.  In  addition, 
p53
Ser15 phosphorylation was analyzed in papers III and IV to monitor the levels of ATM 
activation in response to CLM in the presence or absence of ATM inhibitor. 
In most cases ATM ends up regulating gene expression, whereby p53 and NF- B mediates 
the transcriptional response. Another transcription factor recently found to be regulated by 
ATM  is  the  Ca
2+/cAMP  response  element  binding  protein  (CREB),  which  is  involved  in 
various  cellular  growth  pathways  (Shi  et  al.,  2004).  Interestingly,  ATM  modulates  the 
phosphorylation of CREB in response to ionizing radiation and oxidative stress, leading to 
inactivation  of  CREB.  As  the  NIS  expression  in  thyroid  cells  is  regulated  by  CRE,  the 
relationship between ATM and CREB may be of relevance to the interpretation of some of 
the data presented in this thesis (Chun et al., 2004). 
-H2AX 
ATM also phosphorylates structural components of chromatin in response to DNA damage. 
One  well-studied  target  is  the  histone  variant  H2AX  that  is  intimately  involved  in  the 
recognition of bi-stranded DNA lesions (Rogakou et al., 1998). The nucleosome is a subunit 
of the eukaryotic chromatin composed of approximately 145 bp DNA wrapped around a core 
of eight histone proteins. There are four histone protein families, H4, H3, H2B and H2A. H2A 
consist of three subfamilies, H2AX being one of them comprising 2-10% of the total H2A 
constituent in mammalian tissues.  H2AX is rapidly phosphorylated by ATM on serine 139, 
giving  rise  to  -H2AX,  in  response  to  DNA  DSBs  induced  by  genotoxic  insults.  The 
phosphorylation of H2AX is apparent within a minute and reaches a maximum in 10 minutes 
(Redon  et  al.,  2002).  In  DNA  damaged  cells  antibodies  specific  for  -H2AX  recognizes 
immunofluorescent foci in interphase nuclei and bands on metaphase chromosomes that can 
be counted as a very sensitive measure of the amount of individual DSBs (Rogakou et al., 
1999; Rothkamm and Lobrich, 2003).  -H2AX is dephosphorylated with a half-life of ~2 h, 
similar to the kinetics of DNA repair, resulting in a decrease of the number of foci provided 
that the cell are no longer irradiated or exposed to genotoxic drugs. Thus, monitoring the 
resolution of  -H2AX foci is a method to roughly estimate recovery from DNA damage. DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
  - 26 - 
In papers III-IV  -H2AX phosphorylation and foci formation were determined to characterize 
the ATM-mediated DNA damage response and recovery following irradiation with 
131I and 
exposure to CLM. 
 
ATM Inhibitors 
It is well established that malfunction of DNA checkpoints are important in human pathology, 
especially cancer (Nyberg et al., 2002). As cancer cells often lack one or more checkpoints, 
inhibition of the remaining checkpoints could sensitize the tumor cells to anticancer therapies, 
such as  -irradiation or DNA-damaging drugs (Bartek et al., 2001). Normal cells would still 
be able to activate the other checkpoints and after DNA repair recover from the temporary 
cell-cycle  arrest.  The  fact  that  cells  with  defective  ATM  are  hypersensitive  to  ionizing 
radiation and deficient in repairing all acquired DNA DSBs (Foray et al., 1997) has lead to 
the  proposal  that  ATM  might  be  an  attractive  target  for  the  development  of  new  radio-
sensitizing  agents  (Sarkaria  and  Eshleman,  2001).  Amongst  the  earliest  reported  ATM 
inhibitors were wortmannin and caffeine. However, due to their unspecific binding to ATM 
and  systemic  toxicity  the  identification  and  development  of  more  potent  and  tolerable 
pharmacologic agents were needed (Sarkaria et al., 1998).  
 
KU-55933 
In 2004 Hickson et al. (Hickson et al., 2004) characterized a novel specific inhibitor of the 
ATM kinase named KU-55933, depicted in figure 8. This compound exhibits an IC50 of 12.9 
nmol/L  against  the  ATM  kinase  activity,  acting  through  competitive  binding  to  its  ATP-
binding site. KU-55933 is at least 100-fold more potent inhibiting ATM than the other PI3K 
family members. KU-55933 is able to prevent phosphorylation of p53 on serine 15 (Hickson 
et al., 2004), which is an early event executed by ATM in response to DNA DSB (Shiloh, 
2003). M M. NORDÉN 
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Figure 8.  Chemical structure of KU-55933 [morpholin-4-yl-6-thianthren-1-yl-pyran-4-one]. Modified 
from (Hickson et al., 2004). 
 
In paper IV KU-55933 was employed to elucidate the possible role of ATM in DNA damage-
induced changes of NIS expression and iodide uptake in thyrocytes. 
 
DNA Repair 
As  mentioned  earlier,  DSBs  are  considered  the  most  lethal  form  of  DNA  damage  in 
eukaryotic  cells.  This  is  due  to  the  increased  risk  of  incorrect  repair  that  may  lead  to 
permanent  mutations  or  even  chromosomal  translocations  due  to  the  concurrent  genomic 
instability state. DNA DSBs can be induced by exogenous genotoxic exposures as ionizing 
radiation  and  radiomimetic  chemicals,  or  can  arise  within  the  cell  by  the  action  of 
endogenously produced reactive oxygen species or when the replication fork encounters other 
DNA lesions such as SSBs (Jackson, 2001). DSBs differ from most other types of DNA 
lesions in that they affect both strands of the DNA duplex and therefore prevent use of the 
complementary strand as a template for repair. In order to maintain genomic integrity, higher 
eukaryotes have evolved multiple pathways for the repair of DSBs including homologous 
recombination (HR), non-homologous end-joining (NHEJ), outlined in figure 9 (for a review 
see (Khanna and Jackson, 2001)). NHEJ repairs predominately DSBs in G1 and G0 phases 
whereas HR is most active in S and G2 phase, although, an overlap and competition between 
the two repair mechanisms seem to exist (Burma and Chen, 2004). In HR a homologous DNA 
strand is used as a template for repair of DSB. In NHEJ, on the other hand, double stranded 
DNA is directly joined together and often leads to small DNA sequence deletions, see figure 
8. A range of proteins are critically involved in NHEJ i.e. Ku, DNA-PKcs, Xrcc4 and DNA-DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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ligase IV. The Rad50-Mre11-Nbs1 (RMN) complex, comprising helicase and exonuclease 
activities,  is  involved  in  NHEJ  if  the  DNA  ends  require  processing  before  ligation.  HR 
requires  the  proteins  Rad52  and  Rad51  that  respectively  binds  DNA  ends  and  facilitates 
strand invasion, before the DNA strand is extended by DNA polymerase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  9.  Schematic  picture  of  pathways  involved  in 
repair of double-strand breaks in DNA. NHEJ  rejoins the 
two  broken  ends  directly  often  leading  to  small  DNA 
sequence  deletions.  HR,  on  the  other  hand,  uses  a 
homologous DNA strand as a template and is less prone to 
errors. See text for details.  Modified from (Pichierri et 
al., 2000) 
 
DNA-PK  
The DNA-dependent protein kinase (DNA-PK) is a key enzyme of DNA damage recognition, 
repair and signaling pathways, activated by DNA strand breaks. Mammalian DNA-PK is an 
important component of both the NHEJ pathway for DSB repair and the V(D)J recombination 
(Smith and Jackson, 1999). It is a nuclear serine/threonine kinase comprised of a regulatory 
subunit, containing the Ku70/80 heterodimer, and the 460 kDa catalytic subunit, DNA-PKcs 
(Collis et al., 2004). Like ATM DNA-PK belongs to the PI3K-like family (Shiloh, 2003). It is 
believed that Ku first binds to the DNA ends, before recruiting DNA-PKcs which stabilizes 
its binding to DNA. DNA-PK-deficient cells are defective in the repair of DNA DSBs and M M. NORDÉN 
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display a radiosensitive phenotype (Smith and Jackson, 1999). Additionally, the increased 
susceptibility of the immunodeficient SCID mouse strain to genotoxic insults has been shown 
to be due to a mutation in the gene for DNA-PKcs (Blunt et al., 1995; Lee et al., 1997). DNA-
PK inhibitors may therefore have clinical utility as radio- and chemo-potentiating agents in 
the treatment of cancer. In the search of new potent and selective DNA-PK inhibitors suitable 
for  clinical  purposes  Hollick  et  al.  (Hollick  et  al.,  2003)  synthesized  NU7026,  using 
LY294002 as a structural guide. The molecular structure of NU7026 is depicted in figure 10. 
NU7026 is approximately 6-fold more potent than LY294002, which is a selective ATP-
competitive PI3K inhibitor, inhibiting DNA-PK activity (Izzard et al., 1999). NU7026 has 
been  shown  to  have  a  radiosensitizing  effect  also  in  quiescent  (G0)  cells  by  preventing 
potentially  lethal  damage  recovery  (Veuger  et  al.,  2003),  indicating  that  DNA-PK  is 
important for DNA repair also in quiescent (G 0) cells. 
 
 
 
Figure 10. Chemical structure of NU7026 [2-(morpholin-4-yl)-bezo[h]chomen-4-one]. Modified from 
(Veuger et al., 2003). 
 
In paper III we investigated the possible contribution of DNA repair mechanisms for the 
susceptibility  of  NIS-mediated  iodide  transport  to  DNA  damage  by  using  the  DNA-PK 
inhibitor NU7026.  
 DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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AIMS 
With the aim to elucidate possible molecular mechanisms involved in the thyroid stunning 
phenomenon we investigated the following questions using primary cultured normal thyroid 
cells: 
 
  Is thyroid stunning related to radiation-induced cell cycle arrest? 
  Is  NIS-mediated  iodide  uptake  targeted  in  cells  exposed  to 
131I?  If  so,  is  it  a 
transcriptional response to irradiation?  
  Is  DNA  damage  and  specifically  DNA  DSBs  a  primary  event  inducing  thyroid 
stunning? If so, can DNA repair mechanisms modulate the response?  
  Provided that thyroid stunning can be linked to DNA damage, is the down-stream 
signaling leading to impaired iodide transport ATM-dependent?  M M. NORDÉN 
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RESULTS AND DISCUSSION 
The mechanism causing thyroid stunning remained elusive for many years since the discovery 
more than 50 years ago. However, previous studies in our laboratory (Postgård et al., 2002) 
provided the first experimental evidence indicating that thyroid stunning is a real phenomenon 
and not an artifact related to the methodological difficulties estimating specific radioiodine 
uptake in thyroid tissues from scan images (Brenner, 2002). In the original paper by Postgård 
et al. (Postgård et al., 2002), an absorbed-dose dependent reduction of TSH-stimulated iodide 
transport  in 
131I-irradiated  porcine  thyroid  cells  was  unequivocally  proven.  It  was  further 
found that an absorbed dose of 3 Gy, which is in the dose range received in clinical dosimetric 
scanning  with 
131I,  was  sufficient  to  cause  a  50%  transport  inhibition  compared  to  the 
transport in non-irradiated control cultures. Papers I-IV in this thesis are the result of our 
efforts  to  understand  the  stunning  mechanism  in  more  detail,  the  ultimate  goal  being  to 
suggest possible means of minimizing this unwanted side effect. However, the summarized 
data presented here will be discussed mainly from a biomedical, mechanistic point of view.  
 
Effect of Low Absorbed Doses of 
131I on Iodide Transport (Paper I) 
No information on the lowest absorbed dose from 
131I required to negatively influence iodide 
transport was available. In paper I we therefore investigated the effect of low absorbed doses 
from 
131I on iodide transport in primary porcine thyrocytes cultured on filter in bicameral 
Transwell chambers. According to previous transport studies (Nilsson et al., 1990; Nilsson 
and Ericson, 1994; Postgård et al., 2002), the cells were pre-stimulated with TSH for 48 h in 
order  to  up-regulate  NIS  gene  expression  and  protein  expression  (Riedel  et  al.,  2001). 
Cultures were thereafter continuously exposed to 
131I for additionally 48 h, during ongoing 
TSH-stimulation, after which the basal to apical transepithelial transport of 
125I (used as a 
tracer  in  all  transport  experiments  throughout  the  thesis)  was  monitored.  Transepithelial 
resistance  was  measured  both  before  the  addition  of 
131I  and  the 
125I
--transport  study, 
confirming that a tight monolayer was maintained throughout the study period lasting for up 
to 5 d after start of irradiation. The novel result from this part of paper I was that as low 
absorbed doses as 0.15 Gy from 
131I showed a 20 % inhibition of the iodide uptake. Although 
it is difficult to translate these in vitro dose response findings to a putative clinical situation, DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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paper I suggests that stunning might be recognized at lower absorbed doses than previously 
expected. This in turn indicates that stunning may occur also in 
131I therapy of benign diseases 
such as thyrotoxicosis or Graves’ as patients generally receive a test activity of 0.5 MBq 
corresponding to an absorbed dose of approximately 0.1-0.5 Gy to the thyroid (Berg et al., 
1996).  
 
Effect of 
131I on Cell Proliferation (Paper I) 
Irradiation was conducted on confluent growth-arrested cells in order to avoid confounding 
effects of reduced cell numbers due to radiation-induced cell damage. Loss of cells due to a 
therapeutic effect of 
131I in the experimental model is likely not occurring since no change in 
total DNA content was evident between irradiated and non-irradiated cells in previous studies 
(Postgård et al., 2002). However, whether there is an increased cell turnover rate in irradiated 
cultures has not been investigated, although preliminary findings of only small changes in 
DNA synthesis (measured by [
3H]thymidine incorporation) argue against this possibility (data 
not shown). To further corroborate this, we in paper I determined the lowest absorbed doses 
of 
131I leading to cell cycle arrest. For this purpose we used subconfluent growing thyroid 
cells and compared the effect of 
131I on cell proliferation with that on iodide transport on 
confluent cells. We found that absorbed doses ≥ 1 Gy produced a dose dependent reduction in 
the incorporation of  [
3H]thymidine and  an absorbed dose of  about  4 Gy  was  required to 
enhance a reduction greater than 50%. Quantification of total DNA showed no significant 
change in cell numbers at doses ≤ 3 Gy. It can therefore be excluded that the inhibition of 
iodide transport observed in cultures irradiated with lower absorbed doses is due to altered 
cell number. These data further support the notion that  confluent thyroid cell cultures, in 
which the vast majority of cells are G0, can be safely used to investigate cellular responses to 
131I uncoupled from the mechanisms by which ionizing radiation provokes cell cycle arrest.  
The  finding  that  low  absorbed  doses  0.01  and  0.1  Gy  significantly  decreased  the 
[
3H]thymidine incorporation whereas the slightly higher absorbed doses 0.15 and 0.3 Gy did 
not suggest that proliferating cells might be exceedingly radiosensitive to very low absorbed 
doses of 
131I. It is previously shown that radiation doses ≤ 0.5 Gy are more effective per unit 
in killing cancer cells in vitro than higher doses (Joiner et al., 2001). However, alternative 
explanations  to  small  changes  in  [
3H]thymidine  incorporation  e.g.  reduced  nucleotide M M. NORDÉN 
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transport, cannot be excluded. Further studies are therefore required before a putative hyper-
radiosensitivity interval towards 
131I irradiation can be proven for normal thyroid cells. 
 
Effect of 
131I on NIS mRNA Expression (Paper II) 
To  date  NIS  in  the  basolateral  membrane  and  AIT/SMCT  and  Pendrin,  in  the  apical 
membrane are the only identified iodide transporting molecules in thyroid cells. Defects in 
either one of these proteins alone or in combination could be possible mediators of impaired 
iodide transport explaining thyroid stunning. However, since all iodide transport is governed 
by NIS-mediated uptake, it can be hypothesized that the expression and/or function of NIS is 
the most likely target of ionizing radiation. This possibility was addressed in paper II, in 
which the effect of a moderate high absorbed dose of 
131I (7.5 Gy) on NIS mRNA expression 
in primary cultured thyrocytes was investigated. TSH-stimulated up-regulation of NIS was 
monitored  with  real  time  RT-PCR  using  primers  against  pNIS  according  to  previous  a 
protocol (Tedelind et al., 2006).  Based on the fact that the peak levels of increased NIS 
mRNA occurs 48 h after addition of TSH the cells were, in contrast to earlier transport studies 
(Lundh et al., 2007; Nilsson et al., 1990; Nilsson and Ericson, 1994; Postgård et al., 2002) 
irradiated with 
131I from the start of TSH stimulation. This allowed analysis of the effects of 
irradiation on the neosynthesis of NIS rather than being confounded by possible effects on its 
turnover at steady state (Riedel et al., 2001).  
The data showed that 
131I (7.5 Gy) repressed the NIS mRNA expression by 60-80%, and that 
the reduced transcript levels correlated with a corresponding decrease of iodide transport in 
similarly treated cultures. This implies that the major probable cause of thyroid stunning is 
down-regulation  of  the  NIS  gene.  Exactly  how  the  NIS  transcript  level  is  modulated  in 
response to ionizing radiation was however, not possible to determine in this study. But since 
ionizing  radiation  induces  genotoxic  stress  it  is  possible  that  NIS  is  affected  by  a  stress 
response to DNA damage. As previously mentioned, several signaling pathways converge on 
the NIS promoter regulating its transcriptional activity. These include apart from the TSHR-
cAMP the IGF-I-PI3K/Akt and several MAPK pathways (Pomerance et al., 2000; Taki et al., 
2002). In addition, it can be mentioned that Ref-1, a factor readily activated in response to 
genotoxic stress, is involved the regulation of the NIS promoter (Fritz et al., 2003; Puppin et 
al., 2004).  DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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Effect  of  IGF-I  on  NIS-mediated  Iodide  Transport  after 
131I  Irradiation 
(Paper II) 
In paper II, we further investigated whether the NIS gene transcription stimulated by another 
signaling pathway than TSHR-cAMP also might be radiosensitive. This was based on the 
knowledge from earlier studies performed in our laboratory group showing that IGF-I are able 
to stimulate the transepithelial iodide transport (Ericson and Nilsson, 1996).  
IGF-I alone was found to stimulate NIS expression and iodide transport although much less 
efficiently than TSH. Moreover, the stimulating effect on NIS expression was delayed several 
days implicating that IGF-I probably regulates NIS indirectly. However, together with TSH 
IGF-I accelerated the NIS expression and also counteracted the 
131I-induced loss of NIS. In 
fact, in the presence of IGF-I the magnitude of iodide transport in irradiated cultures were 
greater than that in non-irradiated TSH-stimulated cultures. 
Since IGF-I is known to be mitogenic to confluent cells (Ericson and Nilsson, 1996) it was 
necessary to exclude that the effects of IGF-I was not due to altered cell number. This was 
accomplished by normalizing all NIS mRNA quantifications to the housekeeping gene 18S. 
Moreover, irradiation blocked the IGF-I stimulated increase in total DNA, verifying that the 
observed  effects  on  iodide  transport  were  not  due  to  the  relatively  small  changes  in  cell 
number.  
Another important issue to keep in mind is that IGF-I per se are able to modulate the radiation 
response  that  in  turn  could  influence  cell  behavior.  For  instance,  activation  of  the  IGF-I 
receptor has been reported to induce radioresistance (Yu et al., 2003) and several studies 
(Macaulay et al., 2001; Perer et al., 2000; Wen et al., 2001) have shown that inhibition of 
IGF-I  receptor  signaling  increases  the  radiosensitivity  of  tumor  cells.  Furthermore,  IGF-I 
seems to be linked to the early DNA damage response mediated by ATM, which are able to 
stimulate the IGF-I receptor expression (Peretz et al., 2001; Shahrabani-Gargir et al., 2004) 
and to induce effective DNA repair (Heron-Milhavet et al., 2001).  
The co-stimulating effect of IGF-I and TSH on the 
131I-induced loss of NIS suggests that IGF-
I could be used clinically. However, the diversity of IGF-I effects on NIS among different 
species  must  be  further  examined  before  a  possible  clinical  protocol  could  be  discussed. 
Garcia and Santisteban (Garcia and Santisteban, 2002) have shown that IGF-I suppresses NIS M M. NORDÉN 
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transcription in the rat thyroid cell line, FRTL-5. On the other hand, IGF-I receptor signaling 
is implicated in retinoic acid-stimulated NIS expression in the human breast cancer cell line 
MCF-7 (Kogai et al., 2008a). 
 
Effect of DNA Damage on NIS Expression and Iodide Transport (Paper III 
and IV) 
From the experimental data obtained so far we believe that thyroid stunning is the result of a 
transcriptional blockage of NIS expression in metabolically active cells subjected to low-to-
moderately  high  absorbed  doses  of 
131I.  Still,  it  is  unknown  what  molecular  changes  in 
irradiated thyrocytes lead to repressed NIS activity and loss of iodide uptake. As mentioned 
previously it is conceivable that NIS might be affected by a stress response to DNA damage. 
In paper III we investigated this and particularly whether the formation of DNA DSBs is able 
to trigger and thereby mimic radiation-induced thyroid stunning. The overall DNA damage 
induced  by  ionizing  radiation  is  primarily  SSB  and  base  damage,  and  only  2-5%  of  the 
induced damage is DSB (Elmroth et al., 2003). In these experiments we therefore employed 
calicheamicin   (CLM) to induce high ratio of DSBs. The results unequivocally showed 
that both iodide transport and NIS transcription were strongly suppressed by the genotoxic 
drug administered at subnanonomlar concentrations. 
That  these  very  low  CLM  concentrations  induced  a  typical  DNA  damage  response  was 
evidenced by the formation of  -H2AX foci.   
Moreover,  involvement  of  a  genotoxic  stress  response  was  further  corroborated  by  the 
observation that the DNA-PK inhibitor NU7026 augmented the response to CLM and even 
more interestingly that the NIS mRNA expression and iodide transport were significantly 
reduced  by  NU7026  also  in  the  absence  of  endogenously  induced  DNA  damage.  Again, 
observations of  -H2AX foci in the nuclei of treated cells indicated that the inhibitor in all 
probability interfered with DNA repair, thus arguing against an off-target effect. This notion 
is further supported by earlier studies showing that DNA-PK inhibition potentiates in vitro 
cytotoxicity of ionizing radiation (Jackson, 1997; Rosenzweig et al., 1997) and anticancer 
drugs (Boulton et al., 2000; Kim et al., 2002; Nuno G. Oliveira, 2002).  DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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Paper III provided the first causal evidence of thyroid stunning, linking formation of the most 
serious form of DNA lesion, DSBs, to subsequent repression of NIS gene transcription in 
affected  thyroid  cells.  The  last  paper  of  this  thesis  therefore  focused  on  the  major  DNA 
damage response pathway known to be elicited by DNA DSBs.  
 
Role of ATM in DNA Damage-induced Repression of NIS-mediated Iodide 
Transport (Paper IV) 
ATM  is  the  most  important  key  player  in  the  early  response  to  DNA  DSBs  induced  by 
ionizing radiation (Ismail et al., 2005). The possible involvement of ATM in CLM-induced 
inhibition  of NIS expression and  iodide transport was  therefore investigated  in  paper  IV, 
adopting the experimental approach used in paper II. Cells were pre-treated with the novel 
ATM inhibitor, KU-55933 (Hickson et al., 2004) overnight and then exposed to CLM for 1-2 
h  in  the  continued  presence  of  inhibitor.  This  showed  that  KU-55933  dose  dependently 
reduced ATM-mediated activation of p53 and also counteracted the CLM-induced formation 
of  -H2AX foci, indicating drug specificity. Pre-incubation with the same concentrations of 
KU-55933 were found to significantly counteract the blocking effect of CLM on both iodide 
transport and NIS expression, although restoration was not complete. In contrast, prolonged 
exposure to KU-55933 for 48 h or more reduced the NIS transcript levels giving an opposite 
effect to that monitored after shorter incubations of the drug.  
Putative  down-stream  targets  of  ATM  repressing  NIS  gene  expression  in  DNA  damaged 
thyroid cells remain to be investigated. However, since ATM is implicated in a number of 
signaling cascades several possible mechanisms can be envisaged. Of particular interest is the 
notion that the PKB/Akt protein, commonly known as Akt, plays a key role in the pathway 
related to survival by inhibition of apoptotic signals and promotion of cell cycle progression. 
Akt  signaling  mediates  effects  of  several  growth  factors  e.g.  insulin  or  IGF-I,  and  is 
aberrantly activated in cancer cells (Alessi et al., 1996). Recent findings also indicate that Akt 
participates in the DNA damage response (Brognard et al., 2001). Viniegra et al. (Viniegra et 
al., 2005) found that ATM is an upstream activator of Akt activity, which could explain some 
of the biological symptoms of A-T patients e.g. radiosensitivity and resistance to insulin.  M M. NORDÉN 
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In the PCCl3 thyroid cell line,  Zaballos et al. (Zaballos et al., 2008) recently found that TSH 
stimulates  Akt  phosphorylation  in  a  PI3K-dependent  but  cAMP-independent  manner, 
mediated  by  G   dimers  released  from  Gs  subfamily  upon  TSHR  activation.  Moreover, 
activation  of  this  pathway  was  found  to  negatively  regulate  NIS  gene  expression  by 
decreasing Pax8 binding to the NIS promoter. This suggests a possibility that ATM-mediated 
activation of the PI3K/Akt pathway might provide a direct link between DNA damage and 
inhibited NIS transcription. In line with this hypothesis is the observation that PI3K mediates 
NIS down-regulation in response to IGF-I in FRTL-5 thyroid cells (Garcia and Santisteban, 
2002). However, this possibility is contradicted by to the present findings of a stimulatory 
effect of IGF-I on pNIS (Paper II). A positive regulation of NIS by IGF-I via PI3K is also 
reported for thyroid and breast cancer cells (Knostman et al., 2007; Knostman et al., 2004; 
Kogai et al., 2008b). Thus, involvement of the PI3K/Akt pathway in thyroid stunning requires 
further studies to be elucidated. 
The paradoxical inhibition of pNIS transcription in cells subjected to prolonged exposure to 
KU-55933 might be related to secondary long-term effects of inhibited ATM activity. ATM is 
likely required for the continuous surveillance of DNA integrity, given that if absent DNA 
repair  in  response  to  endogenously  generated  lesions  are  repaired  less  efficiently.  Thus, 
analogous to the effect of DNA-PK inhibition (Paper III), impaired ATM signaling beyond a 
critical time point is assumed to increase  yet poorly understood components of the DNA 
damage  response,  which  may  also  affect  the  transcriptional  control  of  NIS  expression. 
Involvement  of  multiple  pathways  is  supported  by  the  fact  that  KU-55933  only  partially 
reduced  the  NIS  expression  even  though  ATM  kinase  activity  reflected  by  p53 
phosphorylation was nearly completely blocked. It cannot be ruled out, however, that off-
target effects of KU-55933 might contribute at the higher drug concentrations.   DNA DAMAGE AFFECTING THYROIDAL IODIDE TRANSPORT 
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SUMMARY AND CONCLUSIONS 
The work in this thesis was initiated to unravel the mechanism of thyroid stunning, a clinical 
phenomenon that has confused radiation physicists and thyroid oncologist for decades. Using 
an in vitro porcine thyroid cell culture model that allows mimicking of internal radiation with 
131I, we in papers I and II show that: 
1.  Transepithelial iodide transport is decreased by 
131I-irradiation, confirming previous 
findings  in  our  laboratory  (Postgård  et  al.,  2002),  and  that  significant  transport 
inhibition is recognized already at absorbed doses ≤ 1 Gy. 
2.  Absorbed doses of 
131I ≥ 1 Gy are required to inhibit cell proliferation. 
3. 
131I-induced loss of TSH-stimulated iodide transport is paralleled by decreased pNIS 
mRNA levels. 
4.  IGF-I stimulates both NIS mRNA expression and iodide transport in irradiated cells. 
These experimental findings suggest that thyroid stunning likely is due to diminished NIS 
gene transcription as part of the stress response to ionizing radiation. This can partially be 
counteracted by co-stimulation with TSH and IGF-I, possibly representing a radioprotective 
effect.  Furthermore,  iodide  transport  appears  to  be  more  radiosensitive  than  checkpoints 
regulating cell cycle progression in normal thyroid cells. 
In subsequent studies concerning the mechanisms leading to suppressed NIS-mediated iodide 
uptake, we in papers III and IV show that: 
1.  DNA damage and preferably DSBs, induced by the genotoxic drug calicheamicin  1, 
lead to down-regulation of NIS at the transcriptional level and inhibition of TSH-
stimulated iodide transport. 
2.  DNA-damage induced decrease in iodide transport is augmented by a specific DNA-
PK inhibitor (NU7026). 
3.  Specific  blocking  of  ATM  kinase  activity  with  KU-55933  partially  prevents  the 
negative effects of DNA damage on NIS expression and iodide transport. M M. NORDÉN 
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4.  Normal  thyroid  cells  lacking  exogenous  DNA  insults  nearly  abolished  the  NIS-
mediated iodide transport in response to prolonged exposure to ATM inhibitor. 
This provides the first evidence that radiation-induced thyroid stunning in all probability is 
due to DNA DSBs. The notion is supported by the observation that impaired DNA repair 
enhances the stunning effect in vitro. The signaling pathway(s) leading to DNA damage-
induced repression of NIS expression is at least partly dependent of ATM kinase activity. The 
current  model  of  the  stunning  mechanism,  considered  to  be  part  of  the  transcriptional 
response to DNA damage in thyroid cells, is depicted in figure 11. This encourages further 
research  aiming  to  identify  signaling  molecules  down-stream  of  ATM  that  negatively 
regulates the NIS promoter. Knowledge of this will eventually tell us how thyroid stunning 
might be avoided e.g. by pharmacological means in the clinical use of radioiodine. It can also 
be envisaged that identification of signaling intermediates might uncover novel autoregulatory 
mechanisms putatively acting to secure that the NIS expression and iodide uptake is sufficient 
in the normal thyroid gland, even though it throughout life is continuously exposed to very 
high levels of endogenous metabolites e.g. reactive oxygen species harmful to DNA. 
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Figure 11. Summary of present findings indicating the putative signaling pathway(s) involved in DNA 
damage-induced repression of the pNIS gene expression. In addition, the effects of ATM and DNA-PK 
inhibitors  are  indicated:  dotted  lines  indicate  outcome  of  kinase  inhibition,  although  the  precise 
molecular mechanisms are yet unknown. The signaling pathway mediating the radioprotective action 
of  IGF-I  counteracting  down-regulation  of  NIS  is  also  hypothetical.  Not  indicated  in  graph  are 
putative ATM-independent signals that may contribute to loss of NIS-mediated iodide transport in 
DNA-damaged thyroid cells. IR – ionizing radiation; CLM – calicheamicin (for other abbreviations, 
see text of this thesis) M M. NORDÉN 
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